UCB's Global Corporate Website
Welcome to UCB in the United States

Mar

19

Patty Fritz and Bianca Anderson Recognized by the Healthcare Businesswomen’s Association (HBA) as UCB Luminary and Rising Star

Mar

09

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Mar

08

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Mar

07

Innovating and collaborating in immuno-dermatology: a dialogue with UCB’s Simon Lucas & Camille Lee

Mar

06

Putting People First to Create a More Sustainable Healthcare System

Feb

28

UCB on Growth Path for a Decade Plus

Feb

22

Rare Disease Day 2024: The Moment is Now to Be Patient-First to Deliver for People Living with Rare Diseases

Feb

12

Harmony in Health: Partnering for Enhanced Seizure Management and Understanding

Jan

11

Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

Jan

03

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive